Introducing a different type of investment partner

Qral Ventures was founded by a team of experts that can help bridge the gap from early-stage commercialization to commercial launch and success.


As Qral Ventures is the investment arm of Qral Group, our expertise from the executive management services industry gives us a unique approach to set early-stage companies up for commercial success.

Our focus

We provide equity investments to companies that have differentiated technology and cover a high unmet need.


We focus on pre-seed, seed and early Series A stage companies and we support our portfolio companies throughout their lifecycle.


We also work with companies that are building syndicates and we co-invest with our trusted early-stage lead investor network.

Our approach

Our partnership brings the experience, resources, and drive from our investment team.


We leverage the talent and vast human resources from our parent company, Qral Group, to operationally support our portfolio companies from discovery to commercialization.

Our team

Our combined experience and curiosity leads us to build and scale our portfolio companies. We aim to create value for our stakeholders by improving the lives of patients .

Chih-Kao Hu
Managing Partner
Chih-Kao is the managing partner of Qral Ventures and founder of Qral Group, a life-sciences management consulting firm. He is also the CEO of the biotech companies Bluedot Bio and Window Therapeutics . He has expertise from pre-commercial strategy to commercial launch and operations in the pharmaceutical space.Dr. Hu’s background also includes conducting scientific research for EGF-like peptides with Nycomed Pharma AS, out of which led to the discovery of the anticoagulant Angiomax (bivalirudin). He has also conducted research evaluating the pharmacokinetic properties of the anti-fibrinolytic protein, Retavase (BM06.022, recombinant tissue plasminogen activator). He received his MBA from Tepper Business School and Ph.D. from Carnegie Mellon University.
Chih-Kao is the managing partner of Qral Ventures and founder of Qral Group, a life-sciences management consulting firm. He is also the CEO of the biotech companies Bluedot Bio and Window Therapeutics . He has expertise from pre-commercial strategy to commercial launch and operations in the pharmaceutical space.Dr. Hu’s background also includes conducting scientific research for EGF-like peptides with Nycomed Pharma AS, out of which led to the discovery of the anticoagulant Angiomax (bivalirudin). He has also conducted research evaluating the pharmacokinetic properties of the anti-fibrinolytic protein, Retavase (BM06.022, recombinant tissue plasminogen activator). He received his MBA from Tepper Business School and Ph.D. from Carnegie Mellon University.
Dimitra Georganopoulou
General Partner
Dimitra is the General Partner  of Qral Ventures and serves as Chief Business Officer (CBO) in select portfolio companies. She is an experienced biotech professional with extensive knowledge in scouting innovative projects in personalized medicine, therapeutics, devices, diagnostics, and Health IT. She was the Director of Commercialization at Northwestern University, where she supported the launch of multiple startups and helped establish multiple strategic partnerships and licensing deals. She is on the investment committee for various investment programs and a commercialization mentor for many early-stage companies and prestigious innovation education programs. She has previously worked at Baxter supporting late-stage technology scouting and tech assessment for due diligence of M&A deals.Dimitra earned a Ph.D. in Bioelectrochemistry from University College London (UCL).
Dimitra is the General Partner  of Qral Ventures and serves as Chief Business Officer (CBO) in select portfolio companies. She is an experienced biotech professional with extensive knowledge in scouting innovative projects in personalized medicine, therapeutics, devices, diagnostics, and Health IT. She was the Director of Commercialization at Northwestern University, where she supported the launch of multiple startups and helped establish multiple strategic partnerships and licensing deals. She is on the investment committee for various investment programs and a commercialization mentor for many early-stage companies and prestigious innovation education programs. She has previously worked at Baxter supporting late-stage technology scouting and tech assessment for due diligence of M&A deals.Dimitra earned a Ph.D. in Bioelectrochemistry from University College London (UCL).
Firhan Malik
General Partner
Firhan is the General Partner  of Qral Ventures. He brings a vast experience in tech assessment, due diligence, asset acquisitions and market analysis insights. Previously he worked with Semper8 Capital, Pharma Ventures and Willow Tree Capital Group, where he researched investment opportunities. He has spearheaded due diligence on transactions worth an average of $200M+ USD and constructed a network of 500+ life sciences companies. His management consulting experience with multiple Biotech Companies worldwide, includes extensive work in asset acquisitions and market analysis insights, and clinical trial strategy, BD&L, investment and commercial strategies. He has a PhD in Physiology, studying the molecular and physiological links between heart failure and Cystic Fibrosis, at the University of Toronto.
Firhan is the General Partner  of Qral Ventures. He brings a vast experience in tech assessment, due diligence, asset acquisitions and market analysis insights. Previously he worked with Semper8 Capital, Pharma Ventures and Willow Tree Capital Group, where he researched investment opportunities. He has spearheaded due diligence on transactions worth an average of $200M+ USD and constructed a network of 500+ life sciences companies. His management consulting experience with multiple Biotech Companies worldwide, includes extensive work in asset acquisitions and market analysis insights, and clinical trial strategy, BD&L, investment and commercial strategies. He has a PhD in Physiology, studying the molecular and physiological links between heart failure and Cystic Fibrosis, at the University of Toronto.
Daniel Hu
Associate
Daniel joins the team with a rigorous scientific background in Biology at the University of Massachusetts, Amherst. He also brings valuable technical insight from his research at Columbia University, where he developed in vitro models to screen Antibody Drug Conjugates (ADCs) for cancer treatment. As a Qral Group intern-consultant he conducted market research and key opinion leader (KOL) profiling for the pharmaceutical sector.
Daniel joins the team with a rigorous scientific background in Biology at the University of Massachusetts, Amherst. He also brings valuable technical insight from his research at Columbia University, where he developed in vitro models to screen Antibody Drug Conjugates (ADCs) for cancer treatment. As a Qral Group intern-consultant he conducted market research and key opinion leader (KOL) profiling for the pharmaceutical sector.

We strive to build a true partnership to help companies exceed market expectations.